Targovax, a clinical-stage immuno-oncology company developing immune activators to target solid tumours, has agreed terms on a financing of up to gross NOK300m (US$29.5m) with Atlas Special Opportunities via a…
Targovax, a clinical-stage immuno-oncology company developing immune activators to target solid tumours, has agreed terms on a financing of up to gross NOK300m (US$29.5m) with Atlas Special Opportunities via a…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference